|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
chrysoeriol results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene binds to AHR protein] |
CTD |
PMID:20553787 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BGLAP protein] |
CTD |
PMID:20981859 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein] |
CTD |
PMID:20981859 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mtnr1a |
melatonin receptor 1A |
affects binding |
ISO |
chrysoeriol binds to MTNR1A protein |
CTD |
PMID:20399199 |
|
NCBI chr16:47,144,461...47,163,919
Ensembl chr16:47,144,461...47,163,919
|
|
G |
Mtnr1b |
melatonin receptor 1B |
affects binding |
ISO |
chrysoeriol binds to MTNR1B protein |
CTD |
PMID:20399199 |
|
NCBI chr 8:12,638,219...12,652,737
Ensembl chr 8:12,638,219...12,652,737
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Vitamin K 3]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3] |
CTD |
PMID:20399199 |
|
NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFSF11 protein] |
CTD |
PMID:20981859 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
ISO |
[CYP1A1 protein affects the metabolism of scutellarein] which results in increased chemical synthesis of 6-hydroxyluteolin CYP1A1 protein results in increased chemical synthesis of 6-hydroxyluteolin |
CTD |
PMID:19666078 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases chemical synthesis multiple interactions |
ISO |
CYP1B1 protein results in increased chemical synthesis of 6-hydroxyluteolin [CYP1B1 protein affects the metabolism of scutellarein] which results in increased chemical synthesis of 6-hydroxyluteolin |
CTD |
PMID:19666078 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
acivicin inhibits the reaction [S-Nitrosoglutathione results in increased expression of and results in increased stability of CFTR protein]; acivicin inhibits the reaction [S-Nitrosoglutathione results in increased expression of CFTR mRNA] |
CTD |
PMID:14766015 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions decreases activity |
ISO |
[acivicin results in decreased activity of GGT1 protein] which results in decreased susceptibility to Glutathione |
CTD |
PMID:15629191 PMID:19419996 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
|
G |
Mir224 |
microRNA 224 |
decreases expression |
ISO |
C646 decreased expression of miR244 in a human hepatocellular carcinoma cell line |
RGD |
PMID:22459148 |
RGD:18182922 |
NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169
|
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of AKT1 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of AKT1 mRNA] corilagin results in decreased expression of AKT1 protein |
CTD |
PMID:34369273 PMID:34605098 PMID:35084093 PMID:35103375 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of BAX protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2 protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bsg |
basigin |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BSG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP3 protein] corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]] |
CTD |
PMID:34605098 PMID:35103375 PMID:37394652 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP9 protein] |
CTD |
PMID:35103375 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased activity of CAT protein]; corilagin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA] |
CTD |
PMID:30582900 PMID:34605098 PMID:35103375 PMID:35307913 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of FABP3 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:35307913 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA |
CTD |
PMID:35307913 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HIF1A mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HMGB1 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased activity of HMGCR protein] |
CTD |
PMID:34605098 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of IL6 protein] corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]] corilagin results in decreased expression of IL6 protein |
CTD |
PMID:34369273 PMID:34605098 PMID:35084093 PMID:37394652 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Streptozocin results in increased secretion of INS1 protein] |
CTD |
PMID:30582900 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of LDHA mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mb |
myoglobin |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of MB protein] |
CTD |
PMID:34369273 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:35307913 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:35307913 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
corilagin results in decreased expression of NFKB1 protein |
CTD |
PMID:35084093 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
corilagin results in decreased expression of NOS2 protein corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]] |
CTD |
PMID:35084093 PMID:37394652 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of NPPB protein] |
CTD |
PMID:34369273 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
corilagin inhibits the reaction [1-naphthyl isothiocyanate decreases expression of nr1h4 mRNA and protein in rat liver]; corilagin increases expression of nr1h4 mRNA and protein in rat embryonic liver cells |
RGD |
PMID:29235094 |
RGD:15042872 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of PIK3CG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of PPARG protein] |
CTD |
PMID:34605098 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
corilagin results in decreased expression of PTGS2 protein corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]] |
CTD |
PMID:35084093 PMID:37394652 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of SLC16A3 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of TLR2 mRNA]; corilagin inhibits the reaction [Morphine results in increased expression of TLR2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
ISO EXP |
corilagin results in decreased secretion of TNF protein corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]] corilagin results in decreased expression of TNF protein corilagin inhibits the reaction [Doxorubicin results in increased expression of TNF protein] |
CTD |
PMID:12628509 PMID:34369273 PMID:34605098 PMID:35084093 PMID:37394652 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of TNNI3 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:17708605 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA] |
CTD |
PMID:17708605 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGM2 mRNA]; Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGM2 protein] |
CTD |
PMID:17708605 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17708605 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
dihydroouabain promotes the reaction [RORC protein binds to G6PC1 promoter] dihydroouabain results in increased expression of G6PC1 mRNA |
CTD |
PMID:29981919 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
dihydroouabain results in increased expression of and results in increased secretion of IL17A protein |
CTD |
PMID:29981919 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il17f |
interleukin 17F |
multiple interactions |
ISO |
dihydroouabain results in increased expression of and results in increased secretion of IL17F protein |
CTD |
PMID:29981919 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
increases expression multiple interactions |
ISO |
dihydroouabain results in increased expression of NPAS2 mRNA dihydroouabain promotes the reaction [RORC protein binds to NPAS2 promoter] |
CTD |
PMID:29981919 |
|
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Rorc |
RAR-related orphan receptor C |
multiple interactions increases expression |
ISO |
dihydroouabain promotes the reaction [RORC protein binds to G6PC1 promoter]; dihydroouabain promotes the reaction [RORC protein binds to NPAS2 promoter]; RORC protein promotes the reaction [dihydroouabain results in increased expression of RORC mRNA] |
CTD |
PMID:29981919 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand affects the expression of ACP5 mRNA] |
CTD |
PMID:36563736 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form] |
CTD |
PMID:35191607 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]] |
CTD |
PMID:35191607 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases response to substance multiple interactions |
ISO |
diosmetin results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased susceptibility to diosmetin [CYP1A1 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin |
CTD |
PMID:10781868 PMID:21482471 PMID:33727136 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity multiple interactions increases response to substance |
ISO |
diosmetin results in decreased activity of CYP1A2 protein [CYP1A2 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin CYP1A2 protein results in increased susceptibility to diosmetin |
CTD |
PMID:28867436 PMID:33727136 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP1B1 protein |
CTD |
PMID:10781868 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2C19 protein |
CTD |
PMID:28867436 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2C8 protein |
CTD |
PMID:28867436 |
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2E1 protein |
CTD |
PMID:28867436 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of HMOX1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein] |
CTD |
PMID:35191607 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL18 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL18 protein] |
CTD |
PMID:35191607 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL1B protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein] |
CTD |
PMID:35191607 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of KEAP1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]] |
CTD |
PMID:35191607 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36563736 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:36563736 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36563736 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36563736 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand affects the expression of NFATC1 mRNA] |
CTD |
PMID:36563736 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NFE2L2 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]] |
CTD |
PMID:35191607 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16934226 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NLRP3 protein] |
CTD |
PMID:35191607 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:16934226 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NQO1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 protein] |
CTD |
PMID:35191607 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]] |
CTD |
PMID:35191607 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
diosmetin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PYCARD protein] |
CTD |
PMID:35191607 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
EXP |
[diosmetin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:28867436 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:28867436 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:16934226 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Diosmin binds to and results in increased activity of AHR protein |
CTD |
PMID:14644660 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ar |
androgen receptor |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of AR protein] |
CTD |
PMID:31797688 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein] |
CTD |
PMID:21477647 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of BAX protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein] |
CTD |
PMID:21477647 PMID:32061149 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP3 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 PMID:32061149 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP7 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP9 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [Testosterone Propionate results in decreased activity of CAT protein] |
CTD |
PMID:22056647 PMID:23665045 PMID:31797688 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of CEACAM1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of CYP2E1 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of ENO2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of and results in decreased activity of GPX1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of GSR protein]; Diosmin inhibits the reaction [Testosterone Propionate results in decreased activity of GSR protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of GSR protein] |
CTD |
PMID:23665045 PMID:31797688 PMID:32061149 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of IL6 protein] Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of IL6 protein] |
CTD |
PMID:31797688 PMID:32061149 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of KLK3 protein] |
CTD |
PMID:31797688 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of MKI67 protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of MKI67 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Acetic Acid results in increased activity of MPO protein] |
CTD |
PMID:29187079 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of NOS2 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of PARP1 protein] |
CTD |
PMID:32061149 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of PCNA protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PCNA protein] |
CTD |
PMID:23665045 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGER2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of PTGS2 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:23665045 PMID:29187079 PMID:31797688 PMID:32061149 PMID:35920545 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of TNF protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of XDH protein]; Diosmin inhibits the reaction [Testosterone Propionate results in increased activity of XDH protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of XDH protein] |
CTD |
PMID:23665045 PMID:31797688 PMID:32061149 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Acp3 |
acid phosphatase 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ACP3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] |
CTD |
PMID:32971123 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of CYBA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of MYH7 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NCF2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPB mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:38356441 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of AGTR1 protein] |
CTD |
PMID:38356441 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of AIFM1 protein |
CTD |
PMID:23554011 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Ellagic Acid results in increased phosphorylation of AKT1 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of AKT1 protein] |
CTD |
PMID:26986492 PMID:35236242 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] Ellagic Acid binds to ALB protein |
CTD |
PMID:6343536 PMID:25247703 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alkbh2 |
alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of ALKBH2 protein |
CTD |
PMID:31088072 |
|
NCBI chr12:42,494,187...42,500,929
Ensembl chr12:42,496,300...42,500,914
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Ellagic Acid results in increased expression of ALPL mRNA |
CTD |
PMID:38145796 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of APAF1 mRNA Ellagic Acid results in increased expression of APAF1 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Aluminum Chloride results in increased expression of APP protein] |
CTD |
PMID:34944019 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASCL1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASNS mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATF3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATG5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
Ellagic Acid results in increased expression of BAD protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA] Ellagic Acid results in increased expression of BAX mRNA |
CTD |
PMID:29854611 PMID:35179410 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of BCL2 protein Ellagic Acid results in decreased expression of BCL2 mRNA Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA] [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA] |
CTD |
PMID:20103723 PMID:22386815 PMID:29854611 PMID:35179410 PMID:35236242 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BMP6 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brf1 |
BRF1 general transcription factor IIIB subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BRF1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CALR mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions increases activity decreases activity decreases expression |
ISO EXP |
Ellagic Acid results in increased expression of CASP3 mRNA Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]; Ellagic Acid promotes the reaction [sinapinic acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]]; sinapinic acid promotes the reaction [Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]] Ellagic Acid results in increased expression of and results in increased activity of CASP3 protein Ellagic Acid results in increased activity of CASP3 protein Ellagic Acid results in decreased activity of CASP3 protein Ellagic Acid results in decreased expression of CASP3 mRNA |
CTD |
PMID:12002526 PMID:22386815 PMID:23554011 PMID:23811531 PMID:28815802 PMID:29854611 PMID:34661493 PMID:34944019 PMID:35236242 PMID:38356441 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Ellagic Acid results in increased expression of and results in increased activity of CASP9 protein |
CTD |
PMID:23554011 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Ellagic Acid results in increased activity of CAT protein Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] |
CTD |
PMID:20074268 PMID:24877639 PMID:29864931 PMID:35236242 PMID:36108929 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases secretion |
ISO |
Ellagic Acid results in decreased secretion of CCL2 protein |
CTD |
PMID:20816778 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccng1 |
cyclin G1 |
decreases expression |
EXP |
ellagic acid inhibits the reaction [estrogen increases expression of Ccng1 mRNA and protein in rat mammary tissue] |
RGD |
PMID:23791885 |
RGD:151356928 |
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CD14 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CDK1 protein |
CTD |
PMID:23554011 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA] [Ellagic Acid co-treated with Quercetin] results in increased expression of CDKN1A mRNA; Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]] Ellagic Acid results in increased expression of CDKN1A protein |
CTD |
PMID:15735102 PMID:20103723 PMID:23554011 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Ellagic Acid results in increased expression of COL1A1 mRNA; Ellagic Acid results in increased expression of COL1A1 protein |
CTD |
PMID:38145796 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:21762681 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein] |
CTD |
PMID:32971123 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of CYBA mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of CYP1A1 mRNA Ellagic Acid results in decreased activity of CYP1A1 protein |
CTD |
PMID:19329757 PMID:20816778 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Ellagic Acid results in decreased activity of CYP1B1 protein [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:19329757 PMID:20103723 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Daxx |
death-domain associated protein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DAXX mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DFFA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
E4f1 |
E4F transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of E4F1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:13,471,478...13,495,018
Ensembl chr10:13,474,456...13,485,974
|
|
G |
Egr3 |
early growth response 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of EGR3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Endog |
endonuclease G |
increases expression |
ISO |
Ellagic Acid results in increased expression of ENDOG protein |
CTD |
PMID:23554011 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EP300 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EPS15 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
increases expression |
ISO |
Ellagic Acid results in increased expression of EZH1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
F12 |
coagulation factor XII |
multiple interactions increases activity |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] |
CTD |
PMID:6343536 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FGFR1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Flna |
filamin A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FLNA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FN1 protein] |
CTD |
PMID:24877639 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:20103723 PMID:32971123 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased activity of GAL protein] |
CTD |
PMID:27965107 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gpld1 |
glycosylphosphatidylinositol specific phospholipase D1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of GPLD1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:40,084,427...40,132,035
Ensembl chr17:40,084,617...40,126,939
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GPT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of GPT protein] Ellagic Acid inhibits the reaction [Diquat results in increased activity of GPT protein] |
CTD |
PMID:24877639 PMID:29935397 PMID:35268077 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP ISO |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] Ellagic Acid inhibits the reaction [Diquat results in decreased expression of GPX1 mRNA] |
CTD |
PMID:29935397 PMID:35268077 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of GSR protein] |
CTD |
PMID:24877639 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GSTA4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects expression |
EXP |
Ellagic Acid affects the expression of GSTT1 protein |
CTD |
PMID:9855024 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtf2e2 |
general transcription factor IIE subunit 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2E2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:58,399,307...58,449,467
Ensembl chr16:58,399,107...58,449,371
|
|
G |
Gtf2h4 |
general transcription factor 2H subunit 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2H4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:21762681 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of HIF1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of HMOX1 mRNA; Ellagic Acid results in increased expression of HMOX1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of HMOX1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 protein |
CTD |
PMID:22386815 PMID:23546295 PMID:35268077 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene] |
CTD |
PMID:20103723 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Ier2 |
immediate early response 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IER2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG protein] |
CTD |
PMID:29854611 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IGFBP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of IL1B mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] Ellagic Acid inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:18377686 PMID:20816778 PMID:21762681 PMID:24877639 PMID:27965107 PMID:29455002 PMID:29854611 PMID:29864931 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IL1R1 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL6 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL6 protein] |
CTD |
PMID:21762681 PMID:24877639 PMID:27965107 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
increases expression |
ISO |
Ellagic Acid results in increased expression of INPP5D mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
|
|
G |
Iqgap2 |
IQ motif containing GTPase activating protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IQGAP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279
|
|
G |
Irf9 |
interferon regulatory factor 9 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IRF9 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of JUN mRNA; Ellagic Acid results in decreased expression of JUN protein modified form |
CTD |
PMID:23811531 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of KLK3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
increases expression |
ISO |
Ellagic Acid results in increased expression of LITAF mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Map1a |
microtubule-associated protein 1A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP3K1 mRNA; Ellagic Acid results in decreased expression of MAP3K1 protein |
CTD |
PMID:23811531 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32971123 PMID:38356441 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
increases expression |
ISO |
Ellagic Acid results in increased expression of MAPK11 mRNA |
CTD |
PMID:23811531 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of MAPK14 protein] |
CTD |
PMID:27965107 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32971123 PMID:38356441 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:15735102 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15735102 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Ellagic Acid results in decreased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir140 |
microRNA 140 |
multiple interactions |
EXP |
ellagic acid inhibits the reaction [hypoxia and acute myocardial infarction decreases expression of mir140 RNA in cardiac muscle cells] |
RGD |
PMID:28922712 |
RGD:329347824 |
NCBI chr19:35,465,577...35,465,675
Ensembl chr19:35,465,577...35,465,675
|
|
G |
Mmd |
monocyte to macrophage differentiation-associated |
increases expression |
ISO |
Ellagic Acid results in increased expression of MMD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein; zinc chloride inhibits the reaction [Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein] Ellagic Acid results in decreased expression of MMP2 mRNA Ellagic Acid results in decreased activity of MMP2 protein |
CTD |
PMID:21573219 PMID:35179410 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of MMP9 mRNA Ellagic Acid results in decreased activity of MMP9 protein |
CTD |
PMID:35179410 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of MYH7 mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NCF2 mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:32971123 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions increases expression affects response to substance |
ISO EXP |
Ellagic Acid affects the localization of NFE2L2 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein] Ellagic Acid results in increased expression of NFE2L2 mRNA [Ellagic Acid co-treated with Diquat] results in increased expression of NFE2L2 mRNA; Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NFE2L2 mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of NFE2L2 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of and affects the localization of NFE2L2 protein; [Paraquat co-treated with Ellagic Acid] results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of and affects the localization of NFE2L2 protein Ellagic Acid results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of NFE2L2 protein NFE2L2 protein affects the susceptibility to Ellagic Acid |
CTD |
PMID:22386815 PMID:23546295 PMID:30503583 PMID:35236242 PMID:35268077 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NFKB2 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nnat |
neuronatin |
increases expression |
ISO |
Ellagic Acid results in increased expression of NNAT mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Nop56 |
NOP56 ribonucleoprotein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NOP56 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] Ellagic Acid results in decreased expression of NOS2 mRNA |
CTD |
PMID:28815802 PMID:35179410 PMID:38356441 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of NPAS2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPA mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPB mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of NQO1 mRNA; Ellagic Acid results in increased expression of NQO1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NQO1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 protein |
CTD |
PMID:23546295 PMID:35268077 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Ellagic Acid results in increased activity of NR1I3 protein |
CTD |
PMID:21821919 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PARG protein |
CTD |
PMID:19840838 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] |
CTD |
PMID:25247703 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA] |
CTD |
PMID:20103723 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased nitrosation of and results in decreased activity of PDIA2 protein] |
CTD |
PMID:25247703 |
|
NCBI chr10:15,215,824...15,218,937
Ensembl chr10:15,215,824...15,220,931
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PLA2G2A mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Plp2 |
proteolipid protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PLP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:14,834,249...14,837,648
Ensembl chr X:14,834,231...14,838,514
|
|
G |
Pml |
PML nuclear body scaffold |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PML mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PPARD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Ellagic Acid results in increased expression of PPARG protein |
CTD |
PMID:23811531 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of PPARGC1A mRNA] Ellagic Acid results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:30503583 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PRKG1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Ptn |
pleiotrophin |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of PTN mRNA Ellagic Acid results in increased expression of PTN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Ptprn2 |
protein tyrosine phosphatase, receptor type N2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PTPRN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575
|
|
G |
Ran |
RAN, member RAS oncogene family |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RAN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 protein] |
CTD |
PMID:27965107 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of RECK mRNA; Ellagic Acid results in increased expression of RECK protein zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK mRNA]; zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK protein] |
CTD |
PMID:21573219 |
|
NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of RELA mRNA Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein] Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RELA protein] |
CTD |
PMID:12002526 PMID:24877639 PMID:27473819 PMID:27965107 PMID:32971123 PMID:35236242 PMID:38356441 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgs5 |
regulator of G-protein signaling 5 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RGS5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of RUNX2 mRNA; Ellagic Acid results in increased expression of RUNX2 protein |
CTD |
PMID:38145796 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SCD mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Septin2 |
septin 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of SEPTIN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 mRNA]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 protein] |
CTD |
PMID:34944019 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] |
CTD |
PMID:29935397 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SOD3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Ellagic Acid results in increased expression of SP7 mRNA; Ellagic Acid results in increased expression of SP7 protein |
CTD |
PMID:38145796 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of SPP1 mRNA; Ellagic Acid results in increased expression of SPP1 protein |
CTD |
PMID:38145796 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein] |
CTD |
PMID:32971123 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of STAR mRNA Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of STAR mRNA] |
CTD |
PMID:30503583 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression decreases expression |
ISO |
Ellagic Acid results in increased expression of STAT3 mRNA Ellagic Acid results in decreased expression of STAT3 mRNA |
CTD |
PMID:12002526 PMID:20816778 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Taf1c |
TATA-box binding protein associated factor, RNA polymerase 1 subunit C |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TAF1C mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:47,652,451...47,658,971
Ensembl chr19:47,652,452...47,658,971
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
Ellagic Acid results in increased expression of TCF12 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions increases expression |
ISO EXP |
Ellagic Acid inhibits the reaction [Estradiol results in increased expression of TERT mRNA alternative form] Ellagic Acid inhibits the reaction [phosalone results in decreased activity of TERT protein] Ellagic Acid results in increased expression of TERT mRNA alternative form |
CTD |
PMID:19501078 PMID:27965107 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TFAM mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TGFB1 mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein] |
CTD |
PMID:12002526 PMID:24877639 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [TNF protein results in increased activity of and affects the secretion of CXCL8 protein] Ellagic Acid results in decreased expression of TNF mRNA |
CTD |
PMID:21762681 PMID:24877639 PMID:27473819 PMID:27965107 PMID:28815802 PMID:29455002 PMID:29854611 PMID:29864931 PMID:35179410 PMID:35236242 PMID:36108929 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein] Ellagic Acid binds to TNFRSF11A protein |
CTD |
PMID:32971123 |
|
NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid binds to TNFSF11 protein |
CTD |
PMID:32971123 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] |
CTD |
PMID:21762681 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TP53 mRNA; Ellagic Acid results in increased expression of TP53 protein Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein] |
CTD |
PMID:15735102 PMID:23554011 PMID:27965107 PMID:35179410 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of UGP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
|
|
G |
Usp4 |
ubiquitin specific peptidase 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of USP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:109,035,402...109,079,382
Ensembl chr 8:109,036,099...109,080,427
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of VEGFA protein] |
CTD |
PMID:35236242 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of WARS1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of WEE1 protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of ZBTB16 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
G |
Zmym2 |
zinc finger MYM-type containing 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ZMYM2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:31,035,835...31,108,945
Ensembl chr15:31,035,838...31,109,357
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases response to substance increases metabolic processing decreases activity increases expression |
ISO |
CYP1A1 protein results in increased susceptibility to eupatorin CYP1A1 protein results in increased metabolism of eupatorin analog eupatorin analog results in decreased activity of CYP1A1 protein eupatorin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:18454852 PMID:19601638 PMID:21482471 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing increases expression decreases activity |
ISO |
CYP1B1 protein results in increased metabolism of eupatorin analog eupatorin results in increased expression of CYP1B1 mRNA eupatorin results in decreased activity of CYP1B1 protein |
CTD |
PMID:19601638 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2C19 protein |
CTD |
PMID:21093571 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2D6 protein |
CTD |
PMID:21276781 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP3A4 protein |
CTD |
PMID:21276781 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of ABCC1 protein |
CTD |
PMID:34019859 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of ACTA2 protein] |
CTD |
PMID:22446813 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
homoorientin results in decreased phosphorylation of AKT1 protein homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of AKT1 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:24374571 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of BCL2 mRNA] |
CTD |
PMID:22446813 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
homoorientin results in increased expression of CDH1 protein |
CTD |
PMID:34019859 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
homoorientin results in decreased expression of CDH2 protein |
CTD |
PMID:34019859 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of CTNNB1 protein |
CTD |
PMID:34019859 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation |
ISO |
homoorientin results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:34019859 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:22446813 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of LEF1 protein |
CTD |
PMID:34019859 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of MAPK1 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:24374571 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of MAPK3 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:24374571 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
decreases expression |
ISO |
homoorientin results in decreased expression of MMP7 protein |
CTD |
PMID:34019859 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:22446813 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of POU5F1 protein |
CTD |
PMID:34019859 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
homoorientin results in decreased expression of SNAI2 protein |
CTD |
PMID:34019859 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
homoorientin results in decreased expression of SOX2 protein |
CTD |
PMID:34019859 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases expression decreases phosphorylation |
ISO |
homoorientin results in decreased expression of STAT3 protein modified form homoorientin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:34019859 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tcf7 |
transcription factor 7 |
decreases expression |
ISO |
homoorientin results in decreased expression of TCF7 protein |
CTD |
PMID:34019859 |
|
NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of TGFB1 protein] |
CTD |
PMID:22446813 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:22446813 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
homoorientin results in decreased expression of VIM protein |
CTD |
PMID:34019859 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity decreases expression multiple interactions |
ISO |
Luteolin results in increased activity of ABCB1 protein Luteolin results in decreased expression of ABCB1 protein Luteolin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin] |
CTD |
PMID:34217736 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
Luteolin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Luteolin co-treated with Cisplatin] results in increased expression of ABCC2 protein; Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC2 protein] |
CTD |
PMID:23770416 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC4 protein] |
CTD |
PMID:23770416 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects activity |
ISO |
Luteolin affects the activity of ABCG2 protein |
CTD |
PMID:20403331 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [cobaltous chloride results in increased activity of ACHE protein] |
CTD |
PMID:31362009 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; Luteolin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:19747501 PMID:37308028 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Glucose results in increased expression of AGER mRNA] |
CTD |
PMID:19557821 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Luteolin binds to and results in decreased activity of AHR protein Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] |
CTD |
PMID:14644660 PMID:20450880 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression decreases phosphorylation increases phosphorylation |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein] Luteolin results in decreased expression of AKT1 mRNA Luteolin results in decreased phosphorylation of AKT1 protein Luteolin results in increased phosphorylation of AKT1 protein Luteolin inhibits the reaction [Antimycin A results in decreased activity of AKT1 protein]; Luteolin inhibits the reaction [INS1 protein results in increased activity of AKT1 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in decreased expression of AKT1 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein] [Luteolin co-treated with Hydrogen Peroxide] results in increased expression of AKT1 protein; Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased phosphorylation of AKT1 protein] Luteolin results in decreased expression of AKT1 mRNA; Luteolin results in decreased expression of AKT1 protein |
CTD |
PMID:18591783 PMID:18720166 PMID:19344998 PMID:20153296 PMID:20685402 PMID:21782929 PMID:22926442 PMID:25448439 PMID:27474067 PMID:27525270 PMID:32035215 PMID:36819991 PMID:37379125 PMID:38134066 PMID:38230768 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4] |
CTD |
PMID:18096136 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of ASNS mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of ATF6 protein modified form]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of ATF6 protein modified form] |
CTD |
PMID:32407927 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
EXP ISO |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of ATG5 protein] Luteolin results in increased expression of ATG5 protein |
CTD |
PMID:32035215 PMID:32268164 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases expression |
EXP |
Luteolin results in increased expression of ATP7B mRNA |
CTD |
PMID:31201582 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; Luteolin inhibits the reaction [Methamphetamine results in increased expression of BAX protein] Luteolin inhibits the reaction [Cisplatin results in increased expression of BAX protein] Luteolin results in increased expression of BAX protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of BAX protein]; Luteolin affects the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased expression of BAX protein]; Luteolin affects the reaction [Metals, Heavy results in increased expression of BAX protein] |
CTD |
PMID:21601631 PMID:27474067 PMID:27525270 PMID:29115570 PMID:32035215 PMID:32268164 PMID:38103742 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of BCL2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2 protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] Luteolin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:19557821 PMID:25448439 PMID:27474067 PMID:32268164 PMID:38103742 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Luteolin results in decreased expression of BCL2L1 protein Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2L1 protein] |
CTD |
PMID:21601631 PMID:25448439 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
ISO EXP |
Luteolin results in increased expression of BECN1 protein Luteolin inhibits the reaction [Methamphetamine results in increased expression of BECN1 protein] |
CTD |
PMID:32035215 PMID:32268164 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] |
CTD |
PMID:15334063 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased cleavage of CASP1 protein] Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] |
CTD |
PMID:25450234 PMID:34217685 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases cleavage increases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased cleavage of CASP3 protein]; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of CASP3 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Luteolin results in increased expression of and results in increased cleavage of CASP3 protein Luteolin results in increased expression of CASP3 mRNA Luteolin results in increased expression of CASP3 protein Luteolin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Luteolin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein] Luteolin results in increased activity of CASP3 protein Luteolin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased expression of CASP3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:16140950 PMID:18331776 PMID:19397994 PMID:21074525 PMID:21601631 PMID:23770416 PMID:24525192 PMID:27474067 PMID:27489195 PMID:27525270 PMID:29115570 PMID:31201582 PMID:31288002 PMID:32035215 PMID:32268164 PMID:32407927 PMID:33727136 PMID:33827303 PMID:38134066 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Luteolin results in increased activity of CASP7 protein |
CTD |
PMID:21074525 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO EXP |
[Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein] Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein] |
CTD |
PMID:15334063 PMID:16140950 PMID:24525192 PMID:27525270 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions increases cleavage |
ISO EXP |
Luteolin results in increased activity of CASP9 protein Luteolin inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein] Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of CASP9 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of CASP9 protein] Luteolin results in increased cleavage of CASP9 protein |
CTD |
PMID:18331776 PMID:19397994 PMID:21601631 PMID:27474067 PMID:27489195 PMID:29115570 PMID:33827303 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
affects activity multiple interactions decreases activity |
ISO EXP |
Luteolin affects the activity of CAT protein Luteolin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein] Luteolin results in decreased activity of CAT protein Fluorouracil promotes the reaction [Luteolin results in decreased activity of CAT protein]; Luteolin inhibits the reaction [Doxorubicin results in increased activity of CAT protein]; Luteolin promotes the reaction [Fluorouracil results in decreased activity of CAT protein] |
CTD |
PMID:18503759 PMID:31288002 PMID:33827303 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein] |
CTD |
PMID:24134915 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccn5 |
cellular communication network factor 5 |
decreases expression |
ISO |
Luteolin results in decreased expression of CCN5 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Luteolin results in decreased expression of CCNA2 protein |
CTD |
PMID:22926442 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Luteolin results in decreased expression of CCNB1 mRNA; Luteolin results in decreased expression of CCNB1 protein |
CTD |
PMID:18331776 PMID:19397994 PMID:22926442 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Fluorouracil promotes the reaction [Luteolin results in decreased expression of CCND1 protein]; Luteolin promotes the reaction [Fluorouracil results in decreased expression of CCND1 protein] |
CTD |
PMID:31288002 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Calcimycin results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD40 protein] |
CTD |
PMID:16601352 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
ISO |
Luteolin results in decreased expression of CD74 mRNA |
CTD |
PMID:18818744 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of CDH1 protein] |
CTD |
PMID:27474067 PMID:32268164 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions decreases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of CDH2 protein] |
CTD |
PMID:27474067 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of CDH5 mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of CDK1 protein |
CTD |
PMID:22926442 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity decreases expression |
ISO |
Luteolin results in decreased activity of CDK2 protein Luteolin results in decreased expression of CDK2 protein |
CTD |
PMID:11322924 PMID:22926442 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression affects localization multiple interactions |
ISO EXP |
Luteolin results in increased expression of CDKN1A mRNA; Luteolin results in increased expression of CDKN1A protein Luteolin affects the localization of CDKN1A protein Fluorouracil promotes the reaction [Luteolin results in increased expression of CDKN1A protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of CDKN1A protein] |
CTD |
PMID:11322924 PMID:11790449 PMID:19397994 PMID:22926442 PMID:31201582 PMID:31288002 PMID:32268164 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Luteolin results in increased expression of CDKN1B protein |
CTD |
PMID:11322924 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
Luteolin results in decreased expression of CDKN2C mRNA |
CTD |
PMID:18331776 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity |
EXP |
Luteolin results in decreased activity of CES1 protein |
CTD |
PMID:37353134 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of CHUK protein] Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein] |
CTD |
PMID:25448439 PMID:37390879 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of CLDN1 protein]; Luteolin promotes the reaction [decabromobiphenyl ether results in decreased expression of CLDN1 mRNA] |
CTD |
PMID:33675858 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression multiple interactions |
ISO EXP |
Luteolin results in decreased expression of CSF2 mRNA Luteolin inhibits the reaction [Calcimycin results in increased expression of CSF2 mRNA] |
CTD |
PMID:10718847 PMID:17950587 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of CTNNB1 protein |
CTD |
PMID:32268164 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of CXCL12 mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL9 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases response to substance decreases expression increases expression decreases activity |
ISO |
[CYP1A1 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A1 protein promotes the reaction [Luteolin results in increased expression of H2AX protein]; Luteolin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Dust analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of CYP1A1 mRNA] Luteolin results in decreased expression of CYP1A1 protein Luteolin results in increased expression of CYP1A1 mRNA Luteolin affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] Luteolin results in decreased activity of CYP1A1 protein |
CTD |
PMID:16263508 PMID:17090139 PMID:20403331 PMID:20930378 PMID:21482471 PMID:23994263 PMID:29584932 PMID:33727136 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases response to substance multiple interactions decreases expression |
ISO |
Luteolin results in decreased activity of CYP1A2 protein CYP1A2 protein results in increased susceptibility to Luteolin [CYP1A2 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased expression of H2AX protein] Luteolin results in decreased expression of CYP1A2 protein |
CTD |
PMID:29753067 PMID:33727136 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity increases expression |
ISO |
Luteolin results in decreased activity of CYP1B1 protein Luteolin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21482471 PMID:23994263 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
Luteolin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased expression of CYP2E1 protein] |
CTD |
PMID:23770416 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein] Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] |
CTD |
PMID:32407927 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Derl3 |
derlin 3 |
increases expression |
EXP |
Luteolin results in increased expression of DERL3 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
decreases activity |
ISO |
Luteolin results in decreased activity of DHRS11 protein |
CTD |
PMID:30926317 |
|
NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of DNAJB9 mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dram1 |
DNA-damage regulated autophagy modulator 1 |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of DRAM1 protein Fluorouracil promotes the reaction [Luteolin results in increased expression of DRAM1 protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of DRAM1 protein] |
CTD |
PMID:31288002 |
|
NCBI chr 7:22,742,794...22,776,888
Ensembl chr 7:22,742,849...22,776,765
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein] |
CTD |
PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression multiple interactions affects response to substance |
ISO |
Luteolin results in decreased expression of EGFR mRNA EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; Luteolin affects the activity of and results in decreased phosphorylation of EGFR protein; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin results in decreased phosphorylation of and results in increased activity of EGFR protein EGFR protein affects the susceptibility to Luteolin |
CTD |
PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 PMID:36819991 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Luteolin results in increased expression of EGR1 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased phosphorylation of EIF2S1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32407927 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of and results in increased phosphorylation of ERN1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of and results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32407927 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
affects binding multiple interactions |
ISO |
Luteolin binds to ESR1 protein Luteolin inhibits the reaction [Estradiol binds to ESR1 protein] |
CTD |
PMID:14579009 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases activity affects binding |
ISO |
Luteolin results in increased activity of ESR2 protein Luteolin binds to ESR2 protein |
CTD |
PMID:12224631 PMID:16860978 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F11r |
F11 receptor |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of F11R mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
EXP |
Luteolin results in increased expression of FAS mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of FASN mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of FBP1 mRNA |
CTD |
PMID:18331776 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases activity |
ISO EXP |
Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA] Luteolin inhibits the reaction [Calcimycin results in increased expression of FOS mRNA] Luteolin results in decreased activity of FOS protein |
CTD |
PMID:15322261 PMID:16343431 PMID:17950587 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
Luteolin results in decreased activity of FOSB protein |
CTD |
PMID:16343431 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
Luteolin results in increased expression of and results in increased phosphorylation of FOXO3 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; mirdametinib promotes the reaction [Luteolin results in increased expression of FOXO3 protein] |
CTD |
PMID:32268164 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
Luteolin results in increased expression of GADD45B mRNA; Luteolin results in increased expression of GADD45B protein |
CTD |
PMID:18331776 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP |
Luteolin results in increased expression of GCLC mRNA; Luteolin results in increased expression of GCLC protein [Luteolin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:22864849 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
EXP |
Luteolin results in increased expression of GCLM mRNA; Luteolin results in increased expression of GCLM protein |
CTD |
PMID:22864849 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of GFAP protein] |
CTD |
PMID:19747501 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpr35 |
G protein-coupled receptor 35 |
multiple interactions |
EXP ISO |
Luteolin binds to and results in increased activity of GPR35 protein |
CTD |
PMID:20919992 |
|
NCBI chr 9:93,527,165...93,539,573
Ensembl chr 9:93,527,127...93,539,299
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Doxorubicin results in increased activity of GPT protein] |
CTD |
PMID:33827303 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Luteolin co-treated with 4(G)-alpha-glucopyranosyl-rutin] inhibits the reaction [Doxorubicin results in decreased activity of GPX1 protein] |
CTD |
PMID:9242351 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of GSDMD protein] |
CTD |
PMID:34217685 PMID:37379125 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression |
EXP |
Luteolin results in increased expression of GSTA1 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
increases expression |
EXP |
Luteolin results in increased expression of GSTT2 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
CYP1A1 protein promotes the reaction [Luteolin results in increased expression of H2AX protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased expression of H2AX protein] |
CTD |
PMID:33727136 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases activity |
ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased activity of HIF1A protein]; Luteolin promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Luteolin results in increased expression of and results in increased activity of HIF1A protein Luteolin results in decreased activity of HIF1A protein |
CTD |
PMID:19958256 PMID:20153296 PMID:25448439 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of HMOX1 protein] Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; Luteolin promotes the reaction [Irinotecan results in increased expression of HMOX1 mRNA] Luteolin results in increased expression of HMOX1 mRNA; Luteolin results in increased expression of HMOX1 protein [Luteolin results in increased expression of HMOX1 mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; Luteolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein] |
CTD |
PMID:10975858 PMID:22864849 PMID:31091348 PMID:32268164 PMID:34217685 PMID:34699766 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
decreases expression |
EXP |
Luteolin results in decreased expression of HSD17B7 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein] |
CTD |
PMID:32407927 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:15113938 PMID:15322261 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO EXP |
Luteolin results in increased expression of IFNG protein Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:12755373 PMID:18090225 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Luteolin inhibits the reaction [Doxorubicin results in decreased expression of IL10 protein] Luteolin inhibits the reaction [nickel chloride results in increased expression of IL10 protein] |
CTD |
PMID:16934226 PMID:30016632 PMID:33827303 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Calcimycin results in increased expression of IL13 mRNA] |
CTD |
PMID:17950587 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A protein] |
CTD |
PMID:25450234 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL1B protein] Luteolin results in decreased expression of IL1B protein Luteolin results in decreased expression of IL1B mRNA Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [Rotenone results in increased secretion of IL1B protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; Luteolin inhibits the reaction [bisphenol A results in decreased expression of IL1B protein]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]; Luteolin inhibits the reaction [lipoteichoic acid results in increased expression of IL1B] |
CTD |
PMID:18090225 PMID:18946510 PMID:19557821 PMID:20685402 PMID:24134915 PMID:25448439 PMID:25450234 PMID:30016632 PMID:30207190 PMID:31091348 PMID:31362009 PMID:33675858 PMID:33827303 PMID:34217685 PMID:34699766 PMID:37390879 PMID:37563784 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il27 |
interleukin 27 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL27 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Calcimycin results in increased expression of IL3 mRNA] |
CTD |
PMID:17950587 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il33 |
interleukin 33 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Irinotecan results in increased expression of IL33 mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL33 protein] |
CTD |
PMID:34699766 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4] Luteolin inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA] Luteolin results in decreased expression of IL4 protein |
CTD |
PMID:12755373 PMID:16343431 PMID:16601352 PMID:17950587 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases expression |
ISO |
Luteolin results in decreased expression of IL5 protein |
CTD |
PMID:12755373 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL6 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL6 protein] Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein] Luteolin inhibits the reaction [bisphenol A results in decreased expression of IL6 protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 protein] |
CTD |
PMID:11123379 PMID:18720166 PMID:19426678 PMID:24134915 PMID:25448439 PMID:25450234 PMID:30016632 PMID:31091348 PMID:33675858 PMID:37379125 PMID:37390879 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein]; Luteolin inhibits the reaction [INS1 protein results in increased activity of AKT1 protein]; Luteolin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]; Luteolin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [Fructose results in increased expression of INS1 protein] |
CTD |
PMID:18090225 PMID:18591783 PMID:25169908 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:18591783 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides promotes the reaction [IRF3 protein binds to IRF3 protein]]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:19426678 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased phosphorylation of JAK1 protein] |
CTD |
PMID:38103742 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression decreases phosphorylation |
ISO EXP |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of JUN protein Luteolin results in decreased expression of JUN mRNA Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein] Luteolin results in decreased phosphorylation of JUN protein |
CTD |
PMID:15322261 PMID:15334063 PMID:16343431 PMID:17950587 PMID:30133131 PMID:37390879 PMID:38134066 More...
|
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
Luteolin results in decreased activity of JUNB protein |
CTD |
PMID:16343431 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
Luteolin results in decreased activity of JUND protein |
CTD |
PMID:16343431 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of KEAP1 protein] |
CTD |
PMID:33675858 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
multiple interactions |
ISO |
[Rotenone co-treated with Luteolin] results in increased expression of LRRK2 mRNA; Luteolin inhibits the reaction [Rotenone results in increased expression of LRRK2 mRNA] |
CTD |
PMID:30207190 |
|
NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
EXP |
Luteolin results in decreased expression of LSS mRNA |
CTD |
PMID:31201582 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity multiple interactions |
ISO |
Luteolin results in decreased activity of MAOA protein Luteolin inhibits the reaction [[MAOA protein results in increased metabolism of Serotonin] which results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased metabolism of Serotonin] |
CTD |
PMID:23009399 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein; mirdametinib inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:32268164 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases expression decreases phosphorylation increases phosphorylation increases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein] Luteolin results in decreased expression of MAPK1 mRNA Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Luteolin results in decreased phosphorylation of MAPK1 protein Luteolin results in increased activity of MAPK1 protein |
CTD |
PMID:10718847 PMID:15322261 PMID:17950587 PMID:17982879 PMID:19344998 PMID:19557821 PMID:22864849 PMID:25448439 PMID:27474067 PMID:32268164 PMID:33675858 PMID:36819991 PMID:37390879 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
increases phosphorylation |
ISO |
Luteolin results in increased phosphorylation of MAPK10 protein |
CTD |
PMID:21601631 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation increases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein] Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Luteolin results in decreased phosphorylation of MAPK3 protein Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein Luteolin results in increased activity of MAPK3 protein |
CTD |
PMID:10718847 PMID:17950587 PMID:17982879 PMID:19344998 PMID:19557821 PMID:20685402 PMID:25448439 PMID:27474067 PMID:32268164 PMID:33675858 PMID:37390879 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK8 protein Luteolin results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:10718847 PMID:15334063 PMID:21601631 PMID:30133131 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Luteolin results in increased phosphorylation of MAPK9 protein Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:21601631 PMID:30133131 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Luteolin results in decreased expression of MCL1 protein |
CTD |
PMID:33727136 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
EXP |
Luteolin promotes the reaction [Hydrogen Peroxide results in increased expression of MDM2 mRNA] Luteolin results in increased expression of MDM2 mRNA |
CTD |
PMID:27525270 PMID:31201582 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mir320a |
microRNA 320a |
multiple interactions |
EXP |
luteolin inhibits the reaction [ischemia-reperfusion injury increases expression of Mir320a miRNA in nucleus] |
RGD |
PMID:31089916 |
RGD:155882543 |
NCBI chr15:45,516,392...45,516,473
Ensembl chr15:45,516,392...45,516,473
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of MMP1 mRNA; Luteolin results in decreased expression of MMP1 protein |
CTD |
PMID:21112745 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression decreases secretion |
ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein] Luteolin results in increased expression of MMP9 protein Luteolin inhibits the reaction [Carbon Tetrachloride results in decreased expression of MMP9 protein] Luteolin results in decreased secretion of MMP9 protein |
CTD |
PMID:10556937 PMID:15135307 PMID:19747501 PMID:25448439 PMID:30133131 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Doxorubicin results in increased activity of MPO protein] |
CTD |
PMID:33827303 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of MYLK protein]; triptolide inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of MYLK protein]] |
CTD |
PMID:33675858 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of NFAT5 mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
decreases expression |
EXP |
Luteolin results in decreased expression of NFE2 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases activity |
EXP ISO |
[Luteolin results in increased activity of NFE2L2 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium; Luteolin affects the localization of and results in increased activity of NFE2L2 protein; Luteolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein] luteolin inhibits the reaction [ischemia-reperfusion injury increases expression of Nfe2l2 protein in nucleus] Luteolin promotes the reaction [Rotenone results in increased expression of NFE2L2 mRNA] [Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of NFE2L2 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein |
CTD RGD |
PMID:17982879 PMID:22864849 PMID:30207190 PMID:31091348 PMID:32407927 PMID:33675858 PMID:34217685 PMID:34699766 PMID:31089916 More...
|
RGD:155882543 |
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of and affects the localization of NFKB1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein] |
CTD |
PMID:15334063 PMID:18090225 PMID:33675858 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of NFKBIA protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein] Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of and results in increased phosphorylation of NFKBIA protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:11123379 PMID:15322261 PMID:16934226 PMID:18090225 PMID:19557821 PMID:25448439 PMID:33675858 PMID:37390879 More...
|
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]] |
CTD |
PMID:15322261 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of NLRP1A protein] |
CTD |
PMID:25450234 |
|
NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] |
CTD |
PMID:34217685 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] Luteolin results in decreased expression of NOS2 mRNA Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:16934226 PMID:18090225 PMID:19426678 PMID:25448439 PMID:34699766 PMID:37379125 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[Luteolin co-treated with linarin] results in increased expression of NOS3 protein modified form |
CTD |
PMID:29052401 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of NQO1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]] |
CTD |
PMID:33675858 PMID:34699766 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of NR1D1 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
Luteolin results in decreased expression of NSDHL mRNA |
CTD |
PMID:31201582 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of OCLN mRNA]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of OCLN protein] |
CTD |
PMID:33675858 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of P2RX4 protein] |
CTD |
PMID:25450234 |
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO EXP |
[Luteolin co-treated with Paclitaxel] results in decreased expression of PARP1 protein; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of PARP1 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of PARP1 protein]; mirdametinib promotes the reaction [Luteolin results in increased cleavage of PARP1 protein] Luteolin inhibits the reaction [Tunicamycin results in increased expression of PARP1 protein modified form] |
CTD |
PMID:12168845 PMID:24525192 PMID:29115570 PMID:31201582 PMID:32268164 PMID:32407927 PMID:33727136 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of PDGFB mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
Luteolin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of PLK1 protein |
CTD |
PMID:22926442 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of PPARG mRNA [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]]; Luteolin inhibits the reaction [Irinotecan results in decreased expression of PPARG mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]] |
CTD |
PMID:34699766 PMID:37308028 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]] |
CTD |
PMID:37308028 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein] |
CTD |
PMID:30133131 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[Rotenone co-treated with Luteolin] results in increased expression of PRKN mRNA; Luteolin inhibits the reaction [Rotenone results in decreased expression of PRKN mRNA] |
CTD |
PMID:30207190 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Psca |
prostate stem cell antigen |
decreases expression |
ISO |
Luteolin results in decreased expression of PSCA mRNA |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 7:106,598,203...106,603,114
Ensembl chr 7:106,595,284...106,609,746
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of PTEN protein] |
CTD |
PMID:32035215 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Dust analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Dust results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Particulate Matter results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions results in increased expression of PTGS2 mRNA] Luteolin results in increased expression of PTGS2 mRNA Luteolin inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein] |
CTD |
PMID:16263508 PMID:19557821 PMID:23770416 PMID:25448439 PMID:31201582 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions decreases phosphorylation |
ISO |
EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:15135307 PMID:25448439 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of PYCARD protein] |
CTD |
PMID:25450234 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
luteolin decreases expression of RAC1 protein in lung cancer cells |
RGD |
PMID:32256987 |
RGD:153345548 |
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of and affects the localization of RELA protein]; Luteolin inhibits the reaction [Glucose affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein] Luteolin inhibits the reaction [Cisplatin results in increased expression of RELA protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein] |
CTD |
PMID:15113938 PMID:15334063 PMID:18090225 PMID:19557821 PMID:23770416 PMID:25448439 PMID:30133131 PMID:34217685 PMID:37390879 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:15113938 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sesn2 |
sestrin 2 |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of SESN2 mRNA; Luteolin results in increased expression of SESN2 protein Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 protein] [Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] |
CTD |
PMID:32407927 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Luteolin results in increased expression of SFN mRNA; Luteolin results in increased expression of SFN protein |
CTD |
PMID:18331776 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
EXP |
[[Luteolin co-treated with Phloretin] results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate; [Luteolin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
decreases activity |
ISO |
Luteolin results in decreased activity of SLC22A6 protein |
CTD |
PMID:32159797 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
decreases activity |
ISO |
Luteolin results in decreased activity of SLC22A8 protein |
CTD |
PMID:32159797 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [SLC2A1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose] |
CTD |
PMID:36870413 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
multiple interactions |
ISO |
[Luteolin co-treated with Oxygen deficiency] results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:20153296 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] |
CTD |
PMID:18591783 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slco1c1 |
solute carrier organic anion transporter family, member 1c1 |
decreases activity multiple interactions |
EXP |
Luteolin results in decreased activity of SLCO1B1 protein [Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate |
CTD |
PMID:32259555 |
|
NCBI chr 4:174,466,621...174,513,290
Ensembl chr 4:174,466,631...174,513,289
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of SNAI1 protein] |
CTD |
PMID:33675858 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Sod1 |
superoxide dismutase 1 |
affects activity increases expression multiple interactions |
ISO |
Luteolin affects the activity of SOD1 protein Luteolin results in increased expression of SOD1 mRNA Luteolin inhibits the reaction [Irinotecan results in decreased expression of SOD1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of SOD1 mRNA] Luteolin inhibits the reaction [Carbon Tetrachloride results in increased activity of SOD1 protein] |
CTD |
PMID:18503759 PMID:19747501 PMID:34699766 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
Luteolin results in increased expression of SOD2 protein |
CTD |
PMID:32268164 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of SREBF1 mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
EXP |
Luteolin results in increased expression of STAR mRNA; Luteolin results in increased expression of STAR protein |
CTD |
PMID:31201582 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation |
ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of STAT3 protein]; Luteolin promotes the reaction [Paclitaxel results in decreased phosphorylation of STAT3 protein]; Paclitaxel promotes the reaction [Luteolin results in decreased phosphorylation of STAT3 protein] Luteolin inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:24525192 PMID:25448439 PMID:38103742 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
decreases activity |
ISO |
Luteolin results in decreased activity of TBK1 protein |
CTD |
PMID:19426678 |
|
NCBI chr 7:57,077,830...57,110,868
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; Luteolin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:37308028 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 mRNA]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]; ML 7 inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]]; triptolide inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]] |
CTD |
PMID:33675858 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
decreases expression |
EXP |
Luteolin results in decreased expression of TM7SF2 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of TNF protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of TNF protein]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [nickel chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]]; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]] Luteolin results in decreased expression of TNF protein Luteolin results in decreased expression of TNF mRNA Luteolin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein] Luteolin inhibits the reaction [bisphenol A results in decreased expression of TNF protein]; Luteolin inhibits the reaction [Calcimycin results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein] |
CTD |
PMID:11123379 PMID:15113938 PMID:15322261 PMID:15334063 PMID:16934226 PMID:17950587 PMID:18720166 PMID:19426678 PMID:19557821 PMID:23770416 PMID:25448439 PMID:25450234 PMID:30016632 PMID:31091348 PMID:31362009 PMID:33675858 PMID:33827303 PMID:34699766 PMID:37379125 PMID:37563784 PMID:38134066 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:15334063 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased ubiquitination of and results in increased degradation of and results in decreased expression of XIAP protein] |
CTD |
PMID:16140950 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Top1 |
DNA topoisomerase I |
multiple interactions |
EXP |
Luteolin binds to and results in decreased activity of TOP1 protein |
CTD |
PMID:12027807 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression increases expression |
ISO EXP |
Fluorouracil promotes the reaction [Luteolin results in increased expression of TRP53 protein]; Luteolin inhibits the reaction [Cisplatin results in increased expression of TRP53 protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of TRP53 protein] Luteolin results in decreased expression of TRP53 mRNA Luteolin results in increased expression of TP53 mRNA Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased expression of TP53 protein] |
CTD |
PMID:23770416 PMID:27525270 PMID:31201582 PMID:31288002 PMID:32035215 PMID:36819991 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Luteolin results in increased expression of TP53I3 mRNA; Luteolin results in increased expression of TP53I3 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G |
Tp63 |
tumor protein p63 |
increases expression |
ISO |
Luteolin results in increased expression of TP63 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Tp73 |
tumor protein p73 |
increases expression |
ISO |
Luteolin results in increased expression of TP73 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
Luteolin promotes the reaction [Rotenone results in increased expression of TXN1 mRNA] |
CTD |
PMID:30207190 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases activity |
ISO |
Luteolin results in decreased activity of TXNRD1 protein |
CTD |
PMID:31288002 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
Luteolin results in increased expression of TYR mRNA |
CTD |
PMID:21071833 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions increases expression |
ISO |
Luteolin inhibits the reaction [Benzo(a)pyrene results in increased expression of UGT1A1 mRNA] Luteolin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:20403331 PMID:29584932 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
affects glucuronidation increases glucuronidation |
ISO |
UGT1A3 mutant form affects the glucuronidation of Luteolin UGT1A3 protein results in increased glucuronidation of Luteolin |
CTD |
PMID:16738032 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of Luteolin |
CTD |
PMID:32009392 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vav3 |
vav guanine nucleotide exchange factor 3 |
decreases expression |
ISO |
Luteolin results in decreased expression of VAV3 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr 2:197,011,901...197,354,321
Ensembl chr 2:197,011,831...197,354,321
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:15113938 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression multiple interactions |
ISO |
Luteolin results in decreased expression of VEGFA mRNA; Luteolin results in decreased expression of VEGFA protein Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of VEGFA protein]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Luteolin inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; Luteolin inhibits the reaction [Oxygen deficiency results in increased secretion of VEGFA protein] |
CTD |
PMID:19005980 PMID:20153296 PMID:25448439 PMID:26800359 PMID:36819991 PMID:38134066 More...
|
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vwf |
von Willebrand factor |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of VWF mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Wnt3 |
Wnt family member 3 |
decreases expression |
ISO |
Luteolin results in decreased expression of WNT3 protein |
CTD |
PMID:32268164 |
|
NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of XBP1 mRNA alternative form] |
CTD |
PMID:32407927 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Doxorubicin results in increased activity of XDH protein] |
CTD |
PMID:33827303 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Luteolin promotes the reaction [TNFSF10 protein results in increased ubiquitination of and results in increased degradation of and results in decreased expression of XIAP protein] |
CTD |
PMID:16140950 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[luteolin-7-glucoside co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein luteolin-7-glucoside results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31157476 PMID:34165247 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BAX protein |
CTD |
PMID:34165247 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] luteolin-7-glucoside results in decreased expression of BCL2 protein |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of BCL2L1 protein |
CTD |
PMID:34165247 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BID protein alternative form |
CTD |
PMID:34165247 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of CASP3 protein]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP8 protein |
CTD |
PMID:34165247 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP9 protein |
CTD |
PMID:34165247 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:31157476 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNA2 protein |
CTD |
PMID:34165247 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNB1 protein |
CTD |
PMID:34165247 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases phosphorylation |
ISO |
luteolin-7-glucoside results in decreased phosphorylation of CDK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CDK2 protein |
CTD |
PMID:34165247 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of CDKN1A protein |
CTD |
PMID:34165247 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein] luteolin-7-glucoside results in increased activity of ESR1 protein |
CTD |
PMID:31381935 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein] luteolin-7-glucoside results in increased activity of ESR2 protein |
CTD |
PMID:31381935 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of FAS protein |
CTD |
PMID:34165247 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein] |
CTD |
PMID:31381935 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein] |
CTD |
PMID:11123379 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
luteolin-7-glucoside results in decreased phosphorylation of MAPK1 protein 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein] luteolin-7-glucoside results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
luteolin-7-glucoside results in increased cleavage of PARP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; U 0126 inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein] |
CTD |
PMID:34165247 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of RIPK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein] |
CTD |
PMID:31381935 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:11123379 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of TNFRSF1A protein |
CTD |
PMID:34165247 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
monodansylcadaverine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16170020 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression |
ISO |
monodansylcadaverine results in decreased expression of BAD protein |
CTD |
PMID:16170020 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
monodansylcadaverine results in increased expression of BCL2L11 protein |
CTD |
PMID:16170020 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
monodansylcadaverine results in decreased expression of BIRC5 protein |
CTD |
PMID:16170020 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CCL25 protein] |
CTD |
PMID:22341560 |
|
NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CCL5 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CXCL12 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
monodansylcadaverine results in decreased expression of GSK3B protein |
CTD |
PMID:16170020 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [[IGF1 protein results in increased abundance of Reactive Oxygen Species] which results in increased expression of ZNF143 protein]; monodansylcadaverine inhibits the reaction [IGF1 protein results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:20733350 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
monodansylcadaverine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL12B protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL2 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL3 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL4 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased degradation of IRF3 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22341560 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:22341560 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of NFKB1 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Tgm2 |
transglutaminase 2 |
decreases activity |
ISO |
monodansylcadaverine results in decreased activity of TGM2 protein |
CTD |
PMID:16382148 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Ticam2 |
TIR domain containing adaptor molecule 2 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TICAM2 mRNA] |
CTD |
PMID:22341560 |
|
NCBI chr18:39,289,902...39,311,462
Ensembl chr18:39,294,453...39,311,462
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TIMP1 protein] |
CTD |
PMID:22341560 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TIMP4 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of TLR4 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNFRSF1A protein] |
CTD |
PMID:22341560 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Zfp143 |
zinc finger protein 143 |
multiple interactions |
ISO |
monodansylcadaverine inhibits the reaction [[IGF1 protein results in increased abundance of Reactive Oxygen Species] which results in increased expression of ZNF143 protein] |
CTD |
PMID:20733350 |
|
NCBI chr 1:164,109,041...164,144,902
Ensembl chr 1:164,109,116...164,144,902
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [Dexamethasone results in increased expression of ACACA mRNA] |
CTD |
PMID:31053639 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
thermozymocidin results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:31053639 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [Dronabinol results in increased activity of CASP3 protein]; thermozymocidin inhibits the reaction [gamma-Tocopherol results in increased activity of CASP3 protein] |
CTD |
PMID:15596715 PMID:16818650 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [fumonisin B1 results in increased expression of DDIT3 protein]; thermozymocidin inhibits the reaction [Resveratrol results in increased expression of DDIT3 protein] |
CTD |
PMID:24264887 PMID:31891755 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein] |
CTD |
PMID:18787411 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[thermozymocidin results in increased susceptibility to Dexamethasone] which results in decreased expression of FASN mRNA |
CTD |
PMID:31053639 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [fumonisin B1 results in increased expression of HSPA5 protein] |
CTD |
PMID:31891755 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [Dronabinol results in increased expression of and affects the localization of and affects the lipidation of MAP1LC3B protein] |
CTD |
PMID:27635674 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
multiple interactions |
ISO EXP |
thermozymocidin inhibits the reaction [Dronabinol results in increased expression of NUPR1 mRNA] |
CTD |
PMID:16616335 PMID:16818650 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [resveratrol results in decreased activity of ODC1 protein] |
CTD |
PMID:17521618 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
thermozymocidin inhibits the reaction [resveratrol results in increased cleavage of PARP1 protein] |
CTD |
PMID:24264887 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Prkcz |
protein kinase C, zeta |
decreases activity |
ISO |
thermozymocidin results in decreased activity of PRKCZ protein |
CTD |
PMID:31053639 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ADIPOQ protein] |
CTD |
PMID:32044341 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Insr |
insulin receptor |
increases expression |
ISO |
orientin results in increased expression of INSR protein |
CTD |
PMID:32044341 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IRS1 protein] |
CTD |
PMID:32044341 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A protein] |
CTD |
PMID:32044341 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG protein] |
CTD |
PMID:32044341 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARGC1A protein] |
CTD |
PMID:32044341 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:32044341 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
decreases activity |
ISO |
orlistat results in decreased activity of ABHD12 protein |
CTD |
PMID:18657971 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
decreases activity |
ISO |
orlistat results in decreased activity of ABHD16A protein |
CTD |
PMID:18657971 |
|
NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions decreases expression |
ISO |
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Orlistat results in decreased expression of ACACA mRNA |
CTD |
PMID:32347045 PMID:33476690 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Orlistat results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
decreases expression |
ISO |
Orlistat results in decreased expression of ACOT8 protein |
CTD |
PMID:30667213 |
|
NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP ISO |
orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] |
CTD |
PMID:25087745 PMID:33476690 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
orlistat results in increased expression of ATF4 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of BAX mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions |
ISO EXP |
orlistat results in increased activity of CASP3 protein orlistat results in increased cleavage of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA] |
CTD |
PMID:17283163 PMID:20805790 PMID:21723078 PMID:32450208 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO EXP |
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA] |
CTD |
PMID:18796435 PMID:20577697 PMID:32450208 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
orlistat results in increased activity of CASP9 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP9 mRNA] |
CTD |
PMID:20805790 PMID:32450208 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
EXP ISO |
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein |
CTD |
PMID:25087745 PMID:30667213 PMID:32450208 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cck |
cholecystokinin |
multiple interactions decreases secretion |
ISO |
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] orlistat results in decreased secretion of CCK protein |
CTD |
PMID:11408251 PMID:18303078 PMID:18647814 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CCNA2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO |
Orlistat results in increased expression of CCND1 protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein] |
CTD |
PMID:30667213 PMID:32045588 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
Orlistat results in increased expression of CCNE1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd34 |
CD34 molecule |
multiple interactions |
ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein] |
CTD |
PMID:32045588 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK1 protein |
CTD |
PMID:30667213 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK4 protein |
CTD |
PMID:30667213 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Orlistat results in increased expression of CDKN1A protein |
CTD |
PMID:30667213 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
orlistat results in increased expression of CDKN1B protein |
CTD |
PMID:15138278 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cel |
carboxyl ester lipase |
decreases activity |
ISO |
orlistat results in decreased activity of CEL protein |
CTD |
PMID:11592731 PMID:12381337 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Clps |
colipase |
multiple interactions |
ISO |
orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] |
CTD |
PMID:15158758 |
|
NCBI chr20:6,620,529...6,622,709
Ensembl chr20:6,620,529...6,622,689
|
|
G |
Cpb2 |
carboxypeptidase B2 |
decreases expression |
ISO |
orlistat results in decreased expression of CPB2 protein |
CTD |
PMID:16959692 |
|
NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
ISO |
Orlistat results in decreased expression of CPT1A protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CPT2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
Orlistat results in increased expression of CYP3A4 mRNA; Orlistat results in increased expression of CYP3A4 protein |
CTD |
PMID:20599501 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
decreases activity |
ISO |
orlistat results in decreased activity of DAGLA protein |
CTD |
PMID:16466961 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
orlistat results in increased expression of DDIT3 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
orlistat results in increased expression of DDIT4 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
|